In China, lung cancer has the highest morbidity and mortality, which can be said to be a kind of disease that seriously endangers people’s health.Is lung cancer that difficult to cure?

There are a lot of patients with advanced non-small lung cancer abroad. Through CIMAvax vaccine inoculation, it is found that the tumor is getting smaller and smaller and the life is getting better and better.

What is the CIMAvax vaccine?

After more than a decade of development, Cuban molecular immunization experts finally developed the world’s first therapeutic vaccine against non-small cell lung cancer, CIMAvax, in 1999.

Subsequently, CIMAvax lung cancer vaccine was launched in Cuba, venezuela, Peru, Paraguay, Colombia and other countries.In 2012, Cuba successfully developed a second lung cancer vaccine, Vaxira.This makes Cuba the only country in the world to have two lung cancer vaccines.

Clinically, the majority of lung cancer patients with lung cancer vaccine can achieve good results, more than half of the cases showed a reduction in tumor, and increased antibodies.

CIMAvax lung cancer vaccine, in fact, is not our traditional sense of the vaccine, it is a therapeutic vaccine, that is, for patients with confirmed lung cancer injection vaccination, can not prevent cancer, but can greatly extend the survival time of patients, improve the quality of life of patients.

What’s so amazing about CIMAvax?

The growth of lung cancer cells depends on a substance called epidermal growth factor. CIMAvax is a vaccine made up of two proteins, epidermal growth factor and P64K.Once injected into the body, it stimulates the immune system of patients with non-small cell lung cancer to produce antibodies.Antibodies clear the body of epidermal growth factor (egf), causing lung cancer cells to lose nutrients and become “hungry”, unable to proliferate and eventually die.

Normal cells also need epidermal growth factor for growth, but it’s not the only one, so without this protein, normal cells can survive.So the vaccine has fewer side effects.

CIMAvax clinical

The 2008 CIMAvax study in the journal of clinical oncology included 80 patients with non-small cell lung cancer.The median survival time in the CIMAvax group was 11.6 months, compared with 5.3 months in the support group.In contrast, the CIMAvax group lived longer and had fewer side effects.

A multicenter, randomized Ⅲ period, 405 patients with clinical trials, all patients received platinum based chemotherapy (4 cycles) or less.Oxalibo (jiali) for injection is the third generation of platinum anticancer drug, which has better effect and fewer side effects than cisplatin and carboplatin.

405 patients were randomly assigned to receive the best supportive treatment or CimaVax vaccination.The experimental group (270 persons) received cyclophosphamide adjuvant therapy for 3 days after first-line chemotherapy, followed by immunotherapy once a month for 4 weeks.The control group (135) received optimal support therapy.The results showed that among the 405 patients with NSCLC, the median survival time was 12.4 months in the vaccine group and 9.4 months in the single supportive care group.

Treatment and precautions of CIMAvax

CIMAvax vaccine therapy for lung cancer is divided into two phases: induction phase and maintenance phase.

One course of treatment of CIMAvax vaccine for lung cancer is 10 vials of red and blue, equivalent to about 20,200 yuan.Two injections each time, one red and one blue vial each.The first four injections were given at 2 weeks, and the fifth injection was given one month after the last injection.That’s 5 injections per course.

Patients who are allergic to CIMAvax should stop using it immediately.The most frequent adverse reactions that may occur are: local erythema or swelling;Body can appear blush, headache, chills, cramps, anorexia, nausea, fever, hot flashes, breathing difficulties.

Can CIMAvax only be used for lung cancer?

The role of epidermal growth factor receptor (EGFR) in lung cancer, especially non-small cell lung cancer, has been demonstrated.The CIMAvax vaccine, however, is not suitable for all people. It is effective only in patients with advanced non-small cell lung cancer, but not in patients with advanced lung cancer or brain metastases.

Egfr is also a target for cancers such as colorectal cancer, head and neck tumors, breast cancer, and thyroid cancer.If CIMAvax is improved in the future, it could be used to treat other cancers.

Is CIMAvax on the market in China?

There has been no follow-up to the phase 1 CimaVax trial conducted by the Chinese academy of medical sciences in 2013.But China has no trade restrictions.If non-small cell lung cancer patients in China want to be treated with the CIMAvax vaccine, they can go to Cuba to get it through the program.

Clinical trials of the CIMAvax vaccine were launched in the United States in 2018, but the clinical trials require extensive verification.Generally, it takes several years to get FDA approval before it can be marketed in the United States.

Overall, the CIMAvax vaccine has been used in many countries for many years as a new hope for the treatment of non-small cell lung cancer patients.Although lung cancer can not be completely cured, but can greatly prolong the survival of patients, into a chronic disease, some patients can even achieve clinical cure.This is the progress of medical technology!